{
    "nct_id": "NCT04300647",
    "official_title": "A Phase II, Safety, and Efficacy Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Patients With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer",
    "inclusion_criteria": "* Histologically confirmed recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix after progression on or after 1-2 lines of prior systemic chemotherapy in the metastatic/recurrent setting that is not amenable to curative treatment with systemic chemotherapy, surgery, and/or radiotherapy\n* Radiologically-measurable disease\n* Eastern Cooperative Oncology Group (ECOG) performance Status of 0 or 1\n* Cervical cancer tissue for study analysis (archival or fresh biopsy specimen)\n* Life expectancy of at least 12 weeks\n* Adequate hematologic and organ function\n* Female of childbearing potential must be willing to comply with adequate contraception\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Treatment with investigational therapy with therapeutic intent within 28 days prior to randomization\n* Active or untreated central nervous system (CNS) or brain metastases\n* Active or history of autoimmune disease or immune deficiency\n* Active tuberculosis\n* Known, clinically significant liver disease\n* Severe infection per investigator judgement at the time of randomization or any active infection that, in the opinion of the investigator, could impact patient safety\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-CTLA-4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies\n* Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to randomization\n* Treatment with systemic immunosuppressive medications within 1 week prior to randomization or anticipation of need for systemic immunosuppressive medication during study\n* Pregnant or breastfeeding woman\n* Known hypersensitivity to any component of the tiragolumab or atezolizumab formulations",
    "miscellaneous_criteria": ""
}